These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 27593744)
41. [SURGICAL TREATMENT OF PARKINSON'S DISEASE WITH LEVODOPA-INDUCED MOVEMENT DISTURBANCES]. Kostiuk K; Lomadze V; Vasyliv N Georgian Med News; 2018; (280-281):11-16. PubMed ID: 30204087 [TBL] [Abstract][Full Text] [Related]
42. Central pain modulation after subthalamic nucleus stimulation: A crossover randomized trial. Marques A; Chassin O; Morand D; Pereira B; Debilly B; Derost P; Ulla M; Lemaire JJ; Durif F Neurology; 2013 Aug; 81(7):633-40. PubMed ID: 23864314 [TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up of bilateral subthalamic nucleus stimulation in Chinese Parkinson's disease patients. Li J; Zhang Y; Li Y Br J Neurosurg; 2015 Jun; 29(3):329-33. PubMed ID: 25812021 [TBL] [Abstract][Full Text] [Related]
44. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. Rodriguez-Oroz MC; Zamarbide I; Guridi J; Palmero MR; Obeso JA J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1382-5. PubMed ID: 15377681 [TBL] [Abstract][Full Text] [Related]
45. Sedation with α2 Agonist Dexmedetomidine During Unilateral Subthalamic Nucleus Deep Brain Stimulation: A Preliminary Report. Morace R; De Angelis M; Aglialoro E; Maucione G; Cavallo L; Solari D; Modugno N; Santilli M; Esposito V; Aloj F World Neurosurg; 2016 May; 89():320-8. PubMed ID: 26805677 [TBL] [Abstract][Full Text] [Related]
46. Three-dimensional SPACE fluid-attenuated inversion recovery at 3 T to improve subthalamic nucleus lead placement for deep brain stimulation in Parkinson's disease: from preclinical to clinical studies. Senova S; Hosomi K; Gurruchaga JM; Gouello G; Ouerchefani N; Beaugendre Y; Lepetit H; Lefaucheur JP; Badin RA; Dauguet J; Jan C; Hantraye P; Brugières P; Palfi S J Neurosurg; 2016 Aug; 125(2):472-80. PubMed ID: 26745490 [TBL] [Abstract][Full Text] [Related]
47. Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization. Garcia-Garcia D; Guridi J; Toledo JB; Alegre M; Obeso JA; Rodríguez-Oroz MC J Neurosurg; 2016 Nov; 125(5):1068-1079. PubMed ID: 26848922 [TBL] [Abstract][Full Text] [Related]
48. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease. Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905 [TBL] [Abstract][Full Text] [Related]
49. Electrode position determined by fused images of preoperative and postoperative magnetic resonance imaging and surgical outcome after subthalamic nucleus deep brain stimulation. Paek SH; Han JH; Lee JY; Kim C; Jeon BS; Kim DG Neurosurgery; 2008 Nov; 63(5):925-36; discussion 936-7. PubMed ID: 19005383 [TBL] [Abstract][Full Text] [Related]
50. A positive correlation between fractional white matter volume and the response of Parkinson disease patients to subthalamic stimulation. Hamasaki T; Yamada K; Hirai T; Kuratsu J Acta Neurochir (Wien); 2010 Jun; 152(6):997-1006; discussion 1006. PubMed ID: 20174839 [TBL] [Abstract][Full Text] [Related]
54. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Østergaard K; Sunde N; Dupont E Mov Disord; 2002 Jul; 17(4):693-700. PubMed ID: 12210858 [TBL] [Abstract][Full Text] [Related]
55. The effect of dopaminergic therapy on intraoperative microelectrode recordings for subthalamic deep brain stimulation under GA: can we operate on patients 'on medications'? Asha MJ; Kausar J; Krovvidi H; Shirley C; White A; Chelvarajah R; Hodson JA; Pall H; Mitchell RD Acta Neurochir (Wien); 2016 Feb; 158(2):387-93. PubMed ID: 26602236 [TBL] [Abstract][Full Text] [Related]
56. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. Gervais-Bernard H; Xie-Brustolin J; Mertens P; Polo G; Klinger H; Adamec D; Broussolle E; Thobois S J Neurol; 2009 Feb; 256(2):225-33. PubMed ID: 19242649 [TBL] [Abstract][Full Text] [Related]
57. Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon. Simonin C; Tir M; Devos D; Kreisler A; Dujardin K; Salleron J; Delval A; Blond S; Defebvre L; Destée A; Krystkowiak P J Neurol; 2009 Oct; 256(10):1736-41. PubMed ID: 19536584 [TBL] [Abstract][Full Text] [Related]
58. Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study. Tsai ST; Hung HY; Hsieh TC; Lin SH; Lin SZ; Chen SY Clin Neurol Neurosurg; 2013 Oct; 115(10):2082-7. PubMed ID: 23916724 [TBL] [Abstract][Full Text] [Related]
59. Advanced therapies in Parkinson's disease: Long-term retrospective study. Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392 [TBL] [Abstract][Full Text] [Related]
60. Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up. Bonenfant J; Drapier S; Houvenaghel JF; Naudet F; Haegelen C; Sauleau P; Vérin M Parkinsonism Relat Disord; 2017 Jan; 34():20-25. PubMed ID: 27751649 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]